Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01B ANTIMETABOLITES
L01BB Purine analogues
L01BB04 Cladribine
D01370 Cladribine (JAN/USP/INN) <JP/US>
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AA Selective immunosuppressants
L04AA40 Cladribine
D01370 Cladribine (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antimetabolites
Cladribine
D01370 Cladribine (JAN/USP/INN)
Central Nervous System Agents
Multiple Sclerosis Agents
Cladribine
D01370 Cladribine (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D01370 Cladribine (JAN/USP/INN)
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
D01370 Cladribine
Drug classes [BR:br08332]
Antineoplastic
DG02018 Antimetabolite
D01370 Cladribine
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Ribonucleoside-diphosphate reductase
RRM1
D01370 Cladribine (JAN/USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01370
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01370